GOLDEN HOOKAH WINNER: Dope-Smoking, Menstruating Monkey Study Got $3.6 Million in Tax Dollars -
The National Institute on Drug Abuse (NIDA), a division of the federal government’s National Institutes of Health (NIH), has spent $3,634,807 over the past decade funding research that involves getting monkeys to smoke and drink drugs such as PCP, methamphetamine (METH), heroin, and cocaine and then studying their behavior, including during different phases of the female monkeys’ menstrual cycles.
The study also uses “interventions” as “treatment models” for monkeys who have been taught to use drugs.
NIDA wins CNSNews.com's "What Were They Smoking Award"—symbolized by The Golden Hookah (see video)—for sponsoring an outrageous government spending program that sends taxpayer dollars up in smoke.
Precursor research on drug-using monkeys, also funded by NIDA, discovered that after smoking cocaine monkeys exhibited “dilated pupils and slightly agitated, hyperactive behavior”—which helped researchers conclude that the “physiological effects” of cocaine on monkeys “were similar to those reported in studies of human subjects.”
In yet another federally funded study of drug-taking monkeys, the monkeys were sometimes given “trail mix” after “their daily experimental sessions.”
Back in 2001, the NIH gave $328,364 to a project called “A Primate Model of Drug Abuse: Intervention Strategies.” The principal investigator for the project was Dr. Marilyn E. Carroll, a professor in the department of psychiatry at the University of Minnesota.
The description of the grant published by NIH said: “Goals of the proposed research are to use a rhesus monkey model of drug abuse, to study factors affecting vulnerability to drug abuse and to evaluate behavioral and pharmacological treatment interventions. Routes of administration that have been developed in this laboratory will include oral drug self-administration and smoking.”
“Vulnerability factors to be examined,” said the NIH description, “are sex and phase of the menstrual cycle as well as patterns/duration of access to drugs.”
Read more -